Lynparza granted FDA priority review for PROpel
16 August 2022 07:00 BST Lynparza in combination with abiraterone granted Priority Review inthe US for patients with metastatic castration-resistant prostate cancer First PARP inhibitor to demonstrate clinical benefit in combination with a new hormonal agent irrespective of homologous recombination repair (HRR) gene mutations AstraZeneca's supplemental New Drug Application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of adult patients with metastatic